Australia’s bad drug deal

by Stephen Duckett

Australia’s Pharmaceutical Benefits Scheme pays at least $1.3 billion a year too much for prescription drugs. New Zealand, which has capped its budget and appointed independent experts to make decisions, pays a sixth as much as the PBS for the same drugs. This report proposes three ways Australia can regain its lost leadership in pharmaceutical pricing.

Watch an interview with Stephen Duckett

A free public lecture in Canberra hosted by ANU, Stephen Duckett discussed the report findings.

Read Stephen Duckett’s article in The Conversation

Stephen Duckett talks to ABC Health Report presenter Norman Swan about why pharmaceutical prices are too high and what should be done.

He also talks about his report with Amanda Vanstone, presenter of the ABC’s Counterpoint.

Download Report

Download Media Release

Download Stephen Duckett's ANU presentationn

Related Articles


06 March 2017

The role of pharmacists should be overhauled, taking the heat off GPs

Published at The Conversation, 6 March A Grattan Institute report released today, Cutting a better drug deal, calls for a major shake-up of pharmacies and pharmaceutical pricing. The market for…


20 March 2013

Ending Australia’s bad drug deal: the three elements of pharmaceutical pricing reform

Australians are paying far too much for prescription drugs, especially drugs that are no longer under patent. Our pricing system fails at almost every step. There is no drug budget to contain costs…


07 March 2017

Time to slay a pharmaceutical zombie

Published by Inside Story, Tuesday 7 March Among the 2014 federal budget’s “zombie” measures still languishing in parliamentary limbo is a proposal to increase Medicare co-payments and loose…